Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) saw a significant decline in short interest in June. As of June 30th, there was short interest totalling 43,000 shares, a decline of 18.1% from the May 30th total of 52,500 shares. Based on an average daily trading volume, of 43,700 shares, the short-interest ratio is currently 1.0 days. Currently, 0.2% of the shares of the stock are short sold.

Institutional investors and hedge funds have recently made changes to their positions in the business. Two Sigma Advisers LP raised its position in Aquinox Pharmaceuticals by 154.1% during the fourth quarter. Two Sigma Advisers LP now owns 34,300 shares of the company’s stock valued at $74,000 after purchasing an additional 20,800 shares in the last quarter. Highbridge Capital Management LLC raised its position in Aquinox Pharmaceuticals by 57.4% during the fourth quarter. Highbridge Capital Management LLC now owns 755,774 shares of the company’s stock valued at $1,633,000 after purchasing an additional 275,666 shares in the last quarter. Acadian Asset Management LLC raised its position in Aquinox Pharmaceuticals by 22.1% during the first quarter. Acadian Asset Management LLC now owns 603,490 shares of the company’s stock valued at $1,627,000 after purchasing an additional 109,350 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Aquinox Pharmaceuticals by 27.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 350,009 shares of the company’s stock valued at $756,000 after purchasing an additional 74,725 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Aquinox Pharmaceuticals by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 170,483 shares of the company’s stock valued at $368,000 after purchasing an additional 4,280 shares in the last quarter. Institutional investors and hedge funds own 71.69% of the company’s stock.

NASDAQ AQXP opened at $2.41 on Friday. Aquinox Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $3.44. The company has a 50 day simple moving average of $2.42.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.09) earnings per share for the quarter.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers.

See Also: What are earnings reports?

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.